Home Analyst Ratings H.C. Wainwright reiterates Arcadia Biosciences Inc. rating to buy and sets...

H.C. Wainwright reiterates Arcadia Biosciences Inc. [RKDA] rating to buy and sets new price target at $8

H.C. Wainwright maintained its Arcadia Biosciences Inc. [RKDA] rating to the equivalent of a Buy but ‎changed the price target to $8 from $10, in a research note dated Dec 28, 2020. That figure represents ‎around a 67.75% premium from where the company’s shares closed on Thursday. Other analysts also ‎revised their coverage, with H.C. Wainwright’s analysts reiterating the shares to “a Buy” rating in a ‎research note to investors issued in mid August. Meanwhile, Piper Jaffray had lowered its rating on ‎RKDA to “Neutral” from the earlier “an Overweight”, in a research note produced for clients May 12, ‎‎2017. In addition, there was a new coverage from Piper Jaffray on June 09, 2015. The research firm ‎rated RKDA “an Overweight”.

Get the hottest stocks to trade every ‎day before the market opens 100% free. Click here now. 

Is Arcadia Biosciences Inc. [NASDAQ:RKDA] a Good Buy Right Now?

It should be noted that ‎RKDA technical indicators for short, intermediate as well as long term progress have placed an overall ‎average of 100% as Sell. The average signal changed from 96% Sell in the last week and compares with ‎‎64% Sell in the past month. Data from Arcadia Biosciences Inc.’s Trend Spotter indicated that the ‎signals were Weakening. The stock current average is 0.41 million shares in the past 20 days and the ‎short term average signal indicates a 100% Sell. In the last 50 days, the average trading volume was ‎‎0.24 million shares while the medium term average advocated for 100% Sell. The average long-term ‎signal stands at 100% Sell and the 100-day average volume stands at 0.25 million shares.‎‎

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored

RKDA Price Performance

On Wall Street, Arcadia Biosciences Inc. [NASDAQ:RKDA] finished ‎Thursday’s session down -1.15% at $2.58. The stock went up to $2.64 at the same session while its ‎lowest single day price was $2.53. In the last five days, it saw a fall of about -11.95%, Arcadia ‎Biosciences Inc. shares dropped by almost -52.92% since the beginning of the year. However, the ‎share price has dropped to as low as -61.09% below its one year high. On 01/30/20, the company ‎shares recorded $6.48, the highest single-day price it has got to in the last 52-weeks and a 52-week low ‎was seen on 03/23/20, the same year at $2.30. The company’s shares have declined by -58.49% in the ‎past year. The 50-day SMA achieved is $3.08 while the 200-day SMA is $3.42. Volume dropped to 0.21 ‎million from 0.34 million in the previous session.‎‎

RKDA Stock Support And Resistance Levels

On the 24-hour scale, the immediate backing is ‎perceived around 2.53 level, and in case of violation of this particular level, it will cause more drop to ‎‎2.47 level. On the upper level, 2.69 is still the key resistance. The stock may increase to the subsequent ‎resistance at 2.64. The Relative Strength Index (RSI) pinned on the 14-day chart is 35.07, implying a ‎neutral technical stance while the MACD stands at -0.25, meaning price will decrease in the next ‎trading period. Percent R indicator moved to 77.36%, implying bearish price movement. Stochastic %K ‎at 25.79% suggest selling the stock.‎‎

What is the short interest in Arcadia Biosciences Inc.?

Short interest in the Arcadia ‎Biosciences Inc. stock has surged, increasing by 0.1 million shares to total 96780.0 shares on Dec 14, ‎‎2020. The interest had seen shares on Nov 12, 2020 stand at 0.2 million, data from Yahoo Finance ‎shows. The decrease of -106.93% suggests the stock saw some decreased bullish sentiment. The ‎stock’s days to cover (short ratio) moved to while the shorted shares account for just 1.00% of the ‎overall float for the stock.‎‎

Arcadia Biosciences Inc.’s Biggest Shareholders: Who Owns Arcadia Biosciences Inc. ‎‎[RKDA]?

Filings by Sabby Capital LLC showed that the firm now holds a total of 275,123 shares or ‎roughly 2.54% of the outstanding RKDA shares. This means their shares have increased by 215,580 ‎from the 275,123 the investor reportedly held in its prior 13-F filing. With the conclusion of the ‎purchase, The Vanguard Group, Inc. updated stake is worth $853,789. Details in the latest 13F filings ‎reveal that Anson Advisors, Inc. disposed off their -55.27% stake valued at $788,431. During the last ‎quarter, Anson Advisors, Inc. liquidated -292,574 of its shares in Arcadia Biosciences Inc. while GSA ‎Capital Partners LLP bought 100,955 shares. The Geode Capital Management LLC’s holdings currently ‎number 49,105 shares at $126690.9. According to the firm’s last 13F report, Ardsley Advisory Partners ‎LP shares in the company at filing stood at 25,000 shares, roughly $83,250.‎‎

RKDA Earnings Forecast For The Current Quarter

Arcadia Biosciences Inc. [RKDA] is expected ‎to report strong earnings results for the quarter ending on Dec 2020. Consensus estimates give the ‎company expected revenues of $1.09M and an earnings per share of -$0.46 for Dec 2020. Looking ‎further ahead, the company is expected to report revenue of $1.67M at an EPS of -$0.41 for Mar 2021. ‎The estimates represent upside of 509.00% and 33.20% in the company’s revenue and earnings per ‎share, respectively, on a year-on-year basis.‎‎

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

RKDA Earnings Estimates For The Current ‎Year

For the financial year, Arcadia Biosciences Inc. [NASDAQ:RKDA] is expected to bring in ‎revenue of $1.99M. The returns are nearly $0.82 million higher than the company’s actual revenue ‎recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -2.17, higher than that ‎of FY19 by $2.36. Estimates put this year’s earnings growth at 52.10%, 33.20% for the next, and at an ‎annual 14.96% over the next 5-year period. As for sales, forecasts are for an increase of 70.20% in the ‎current fiscal year and a further 509.00% over the following year.‎

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Adial Pharmaceuticals Inc. (ADIL) stock plunged during pre-market trading. Here’s to know why?

Adial Pharmaceuticals Inc. (NASDAQ: ADIL) stock gained by 9.06% at last close while the ADIL share price fell by 6.07% in the pre-market trading...

Why AbCellera Biologics Inc. (ABCL) stock faced negativity on Tuesday?

AbCellera Biologics Inc. (ABCL) shares lost 2.13% in after-hours on Tuesday, June 22, 2021, and closed the day at $21.60 per share. Earlier, ABCL's...

Biocept Inc. (BIOC) stock surged during current market trading. Why is it so?

Biocept Inc. (NASDAQ: BIOC) stock gained by 3.13% in the current market trading. Biocept creates and sells molecular diagnostic tests that offer doctors with...

Comstock Mining Inc. (LODE) stock soar during pre-market trading. What’s happening?

Comstock Mining Inc. (NASDAQ: LODE) stock gained by 1.14% at last close while the LODE stock price surged by 3.10% in the pre-market trading...

Why MediciNova Inc (MNOV) stock facing negativity since Monday’s after-hours?

MediciNova Inc. (MNOV) shares lost 5.71% in after-hours on Monday, June 21, 2021, and the plummeting continues in the pre-market session on Tuesday as...

Histogen Inc. (HSTO) stock plunged during pre-market trading. What’s driving it low?

Histogen Inc. (NASDAQ: HSTO) stock gained by 16.16% at last close whereas the HSTO stock price declines by 2.73% in the pre-market trading. Histogen...

Pyxis Tankers Inc. (PXS) stock fell during pre-market trading. Why so?

Pyxis Tankers Inc. (NASDAQ: PXS) stock declined by 0.06% at the last close while the PXS stock price plunged by 6.15% in the pre-market...

Why STAAR Surgical Company (STAA) stock went up on Tuesday?

STAAR Surgical Company (STAA) shares rose 5.84% in after-hours on Tuesday, June 22, 2021, and closed the day at $151.25 per share. earlier in...

Related News

Ocugen Inc. (NASDAQ:OCGN) stock plunged in the premarket trading session; here’s why

At last check Ocugen Inc. (OCGN) stock had plunged by-11.92% to $9.61 in premarket trading session. OCGN stock previously closed at $10.91 losing -12.79%....

KeyBanc reiterates Magna International [MGA] rating to Overweight and sets new price target at $86

KeyBanc maintained its Magna International rating to the equivalent of Overweight but changed the price target to $86.0 from $72, in a research...

Jefferies upgrades Medifast [MED] to Buy rating with a $265 price target

Jefferies took its Medifast rating to the equivalent of Buy from Hold, and the price target to $265.0 from $205, in a research...

American Eagle Outfitters [AEO] Upgraded to Outperform at RBC Capital

RBC Capital took its American Eagle Outfitters rating to the equivalent of Outperform from Sector Perform, and the price target to $30.0 from...

KeyBanc reiterates Nike [NKE] rating to Overweight and sets new price target at $180

KeyBanc maintained its Nike rating to the equivalent of Overweight but changed the price target to $180.0 from $174, in a research note...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.